Abstract: The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.

Abstract: The invention herein discloses histamine-producing bacterial strains for use in the prophylaxis, inhibition, treatment or reducing a risk of relapse of cancer, including colorectal cancer. The present invention also discloses the use of histamine-producing bacterial strains for manufacturing a medicament for treatment of cancer, including male colorectal cancer.

Abstract: The invention relates to selection of bacterial strain for use in treating serotonin deficiency and/or a disease related to serotonin deficiency by culturing bacteria of a lactic acid producing bacterial strain, under aerobic conditions, in a culture medium comprising tryptophan. Any serotonin produced by the bacteria of the lactic acid producing bacterial strain in the culture medium is detected and the lactic acid producing bacterial strain is selected as effective in treating serotonin deficiency and/or a disease related to serotonin deficiency in a subject if serotonin is detected in the culture medium.

Abstract: The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.

Abstract: Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is then selected for use in prophylaxis, inhibition and/or treatment of the allergy.

Abstract: Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is then selected for use in prophylaxis, inhibition and/or treatment of the allergy.

Abstract: The present invention relates to novel Lactic Acid Bacteria strains Lactobacillus reuteri selected from the group comprising Lactobacillus reuteri DSM 32229, Lactobacillus reuteri DSM 32230, Lactobacillus reuteri DSM 32231 and Lactobacillus reuteri DSM 32232 and products comprising these strains. The present invention also relates to a use of one or more Lactic Acid Bacteria strains as a probiotic for the treatment of an inflammation and infection, such as mastitis and/or thrush, especially after topical administration of said strains.

Abstract: Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is then selected for use in prophylaxis, inhibition and/or treatment of the allergy.

Abstract: The invention is directed to a method of treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, thereby treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof. Compositions for use in such methods are also provided.

Abstract: The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.

Abstract: The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.

Abstract: The present invention relates to novel Lactic Acid Bacteria strains Lactobacillus reuteri selected from the group comprising Lactobacillus reuteri DSM 32229, Lactobacillus reuteri DSM 32230, Lactobacillus reuteri DSM 32231 and Lactobacillus reuteri DSM 32232 and products comprising these strains. The present invention also relates to a use of one or more Lactic Acid Bacteria strains as a probiotic for the treatment of an inflammation and infection, such as mastitis and/or thrush, especially after topical administration of said strains.

Abstract: The invention herein discloses histamine-producing bacterial strains for use in the prophylaxis, inhibition, treatment or reducing a risk of relapse of cancer, including colorectal cancer. The present invention also discloses the use of histamine-producing bacterial strains for manufacturing a medicament for treatment of cancer, including male colorectal cancer.

Abstract: The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.

Abstract: The present invention aims to prevent and/or treat health-related conditions in infants born with a non-optimal intestinal microbiome, by providing specific probiotic lactic acid bacterial strains to the pregnant mother. This will enable early colonization of the infant gut, even before birth, and thus prevent and/or treat health-related conditions associated with non-optimal microbiome. Thus, the present invention provides a probiotic microorganism for use in the treatment of a fetus or neonate, wherein said probiotic microorganism is administered to the oral cavity of a pregnant female in a formulation suitable to colonize the oral cavity, wherein said probiotic microorganism is thereby administered to the fetus.

Abstract: The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.

Abstract: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.

Abstract: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.

Abstract: A specific method is provided of improving immunomodulatory properties of Lactobacillus strains using growth media with a specific primary carbon source, including a method of increasing the anti-inflammatory effect of non-pathogenic anti-inflammatory bacterial strains, by the use of specific growth conditions.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.